Botond Roska and José-Alain Sahel win the Wolf Prize
2024 in the field of medicine
Botond Roska and José-Alain Sahel have been awarded the Wolf Prize in Medicine for their pioneering work on restoring vision to blind patients using optogenetic therapy.
05 July 2024
Wolf Prize, considered one of the most prestigious international awards, recognizes
outstanding achievements in various fields including medicine and endowed with 100,000 dollars.
Botond Roska, Director at the Institute of Molecular and Clinical Ophthalmology Basel (IOB) and Professor at the University of Basel, and José-Alain Sahel, Chair of Ophthalmology at the University of Pittsburgh School of Medicine and Chair of IOB's Scientific Advisory Board, have collaborated since 2001. Their work focuses on optogenetic vision restoration, a technique that creates light-sensitive cells using genes derived from algae, to treat degenerative retinal diseases.
In 2021, they reported groundbreaking results from an early-stage clinical trial with blind retinitis pigmentosa patients. One patient who completed the full study protocol was able to detect and move objects placed before him within months of treatment. This work, which was done in collaboration with researchers from the Institut de la Vision in Paris, marked the first proof-of-concept for optogenetics in human disease.
The collaboration between Roska, a basic scientist with an MD, and Sahel, an accomplished clinician and expert in translational research, has proven highly complementary. Their work represents a significant milestone in treating blinding conditions affecting millions worldwide, with promising results emerging from ongoing clinical trials.
About IOB
At the Institute of Molecular and Clinical Ophthalmology Basel (IOB), basic researchers and clinicians work hand in hand to advance the understanding of vision and its diseases, and to develop new therapies for vision loss. IOB started its operations in 2018. The institute is constituted as a foundation, granting academic freedom to its scientists.
Founding partners are the University Hospital Basel, the University of Basel and Novartis. The Canton of Basel-Stadt has granted the institute substantial financial support.
